Protalex, Inc. (PRTX) Findings From Phase 1b Dose Escalation Study of PRTX-100 in Patients With Active Rheumatoid Arthritis  
7/26/2012 10:15:37 AM

SUMMIT, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX), a clinical stage biopharmaceutical company that is developing a class of drugs designed to treat a wide array of autoimmune and inflammatory diseases today announced preliminary findings from its recently completed Phase 1b randomized, multiple-dose, dose-escalation study. The study based in South Africa of PRTX-100 in adult patients with active rheumatoid arthritis (RA) demonstrated that PRTX-100 was generally safe and well tolerated in patients with active RA at all dose levels.